Diabetic dyslipidemia or 'diabetes lipidus'?

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 3, 2011, Pages 341-348

  Muačević Katanec, Diana ^a   Reiner, Željko ^a  

^a KBC Zagreb   (Croatia)

Author keywords

atherogenesis; diabetic dyslipidemia; glucotoxicity; lipotoxicity; Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; TRIACYLGLYCEROL;

APOPTOSIS; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CYTOTOXICITY; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; FLUSHING; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LIPID METABOLISM; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; REVIEW; RISK FACTOR; SIDE EFFECT; SMOKING;

ANIMALS; APOPTOSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; HUMANS; HYPERGLYCEMIA; RISK FACTORS;

EID: 79953246607     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.17     Document Type: Review

References (65)

1. Merkler M, Reiner Ž. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundament. Clin. Pharmacol. 21(Suppl. 2), 1-3 (2007). (Pubitemid 350132286)
2. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87, 4-14 (2010).
3. Roglic G, Unwin N. Mortality attributable to diabetes: Estimates for the year 2010. Diabetes Res. Clin. Pract. 87, 15-19 (2010).
4. Taskinen MR. Diabetic dyslipidaemia. Atherosclerosis (Suppl. 3), 45-51 (2002).
5. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16, 434-444 (1993). (Pubitemid 23046633)
6. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet 352(9131), 837-853 (1998).
7. Chalmers J, Cooper ME. UKPDS and the legacy effect. N. Engl. J. Med. 359, 1618-1620 (2008).
8. Lopes-Virella MF, Carter RE, Gilbert GE et al. Risk factors related to inflammation and endothelial dysfunction in the DCCT/ EDIC Cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care 31, 2006-2012 (2008).
9. Landmesser U, Harrison DG, Drexler H. Oxidant stress: A major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur. J. Clin. Pharmacol. 62(Suppl. 1), 13-19 (2006).
10. Bendall JK, Rinze R, Adlam D, Tatham AL, de Bono J, Channon KM. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II studies in endothelialtargeted Nox2 transgenic mice. Circ. Res. 100, 1016-1025 (2007). (Pubitemid 46598926)
11. Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee JD. Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J. Biol. Chem. 271, 16586-16590 (1996). (Pubitemid 26239014)
12. Xinchun P, Chen Y, Berk BC. Big mitogen-activated protein kinase (BMK1)/ ERK5 protects endothelial cells from apoptosis. Circ. Res. 94, 362-369 (2004). (Pubitemid 38240728)
13. Woo CH, Shishido T, McClain C et al. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stressinduced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ. Res. 102, 538-545 (2008). (Pubitemid 351416753)
14. Griffin E, Re A, Hamel N et al. A link between diabetes and atherosclerosis: Glucose regulates expression of CD36 at the level of translation. Nat. Med. 7, 840-846 (2009).
15. Fuchs FD. The ADVANCE trial. Lancet 371(9606), 25 (2008).
16. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N. Engl. J. Med. 358, 2545-2559 (2008).
17. Drexel H, Aczel S, Marte T et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28, 101-107 (2005). (Pubitemid 40095790)
18. Chapman MJ. Metabolic syndrome and Type 2 diabetes: Lipid and physiological consequences. Diab. Vasc. Dis. Res. 4(Suppl. 3), S5-S8 (2007). (Pubitemid 350013470)
19. Fruchart JC, Sacks F, Hermans MP et al. The residual risk reduction initiative: A call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol. 102, 1K-34K (2008).
20. Betteridge DJ, Morrell JM. Clinicians' Guide to Lipids and Coronary Heart Disease. Chapman & Hall, London, UK, 16 (1998).
21. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr. Opin. Lipidol. 5, 339-349 (1994). (Pubitemid 24341343)
22. Ginsberg H, Plutzky J, Sobel BE. A review of metabolic and cardiovascular effects of oral antidiabetic agents: Beyond glucoselevel lowering. J. Cardiovasc. Risk 6, 337-346 (1999). (Pubitemid 30025631)
23. Durrington PN. Lipids and their metabolism. In: Hyperlipidaemia, Diagnosis and Management (2nd Edition). Butterworth-Heinemann, Oxford, UK (1995).
24. Goldberg IJ. Diabetic dyslipidemia: Causes and consequences. J. Clin. Endocrinol. Metab. 86(3), 965-971 (2001).
25. Stralfors P, Honnor RC. Insulin-induced dephosphorylation of hormone-sensitive lipase. Correlation with lipolysis and cAMP-dependent protein kinase activity. Eur. J. Biochem. 182, 379-385 (1989). (Pubitemid 19165422)
26. Durrington P, Sniderman A. Secondary hyperlipidemia. In:Hyperlipidemia. Durrington P, Sniderman A (Eds). Health Press, Oxford, UK, 71-89 (2002).
27. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulinresistant state. Diabetes Care 19, 390-393 (1996). (Pubitemid 26115468)
28. Dixon JL, Furukawa S, Ginsberg HN. Oleate stimulates secretion of apolipoprotein B-containing lipoproteins from Hep G2 cells by inhibiting early intracellular degradation of apolipoprotein B. J. Biol. Chem. 266, 5080-5086 (1991). (Pubitemid 21909463)
29. Taghibiglou C, Carpentier A, van Iderstine SC et al. Mechanisms of hepatic very LDL overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructosefed hamster model. J. Biol. Chem. 275, 8416-8425 (2000). (Pubitemid 30180185)
30. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very LDL production in humans. J. Clin. Invest. 95, 158-166 (1995).
31. Krauss RM. Lipids and lipoproteins in patients with Type 2 diabetes. Diabetes Care 27(6), 1496-1504 (2004). (Pubitemid 38680002)
32. Lee ET, Welty TK, Fabsitz R et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: Design and methods. Am. J. Epidemiol. 132, 1141-1155 (1990).
33. Gotto AM Jr, Whitney E, Stein EA et al. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Eur. Heart J. 21(19), 1627-1633 (2000).
34. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Eur. Heart J. 28, 2375-2414 (2007).
35. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet 358(9298), 2026-2033 (2001). (Pubitemid 34084825)
36. Durrington P, Sniderman A. Epidemiology and pathophysiology. In:Hyperlipidemia Durrington P, Sniderman A (Eds). Health Press, Oxford, UK, 71-89 (2002).
37. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96, 1221-1232 (2005). (Pubitemid 40962099)
38. Reiner Ž. How to improve cardiovascular diseases prevention in Europe? Nutr. Metab. Cardiovasc. Dis. 19, 451-454 (2009).
39. Verges B, Brun JM, Vaillant G et al. Influence of obesity and hypertriglyceridaemia on the low HDL2-cholesterol level and on its relationship with prevalence of atherosclerosis in Type 2 diabetes. Diabetes Metab. 18(4), 289-297 (1992).
40. Rashid S, Barrett PH, Uffelman KD et al. Lipolytically modified triglyceride-enriched HDLs are rapidly cleared from the circulation. Arterioscler. Thromb. Vasc. Biol. 22, 483-487 (2002). (Pubitemid 34218758)
41. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: A new therapeutic target at the crossroads of dyslipidaemia, inflammation, and atherosclerosis. Pharmacol. Rev. 58, 342-374 (2006). (Pubitemid 44394906)
42. Benedict C, Scheller J, Rose-John S, Born J, Marshall L. Enhancing influence of intranasal interleukin-6 on slow-wave activity and memory consolidation during sleep. FASEB J. 23(10), 3629-3636 (2009).
43. Peter CH, Castellt JV, Andust T. Interleukin-6 and the acute phase response. Biochem. J. 265, 621-636 (1990).
44. Muacevic-Katanec D, Bradamante V, Poljicanin T et al. Clinical study on the effect of simvastatin on paraoxonase activity. Arzneimittelforschung 57(10), 647-653 (2007). (Pubitemid 350075410)
45. Van Lenten BJ, Hama SY, de Beer FC et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest. 96, 2758-2767 (1995).
46. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 15, 1812-1818 (1995).
47. La Du BN, Novais J. Human serum organophosphatase: Biochemical characteristics and polymorphic inheritance. In:Enzymes Hydrolysing Organophosphorus Compounds Reiner E, Aldridge WN, Hoskin FCG (Eds). Ellis-Horwood, Chichester, UK, 41-52 (1989).
48. Lee ET, Welty TK, Fabsitz R et al. The Strong Heart Study. A study of cardiovascular disease in American Indians: Design and methods. Am. J. Epidemiol. 132, 1141-1155 (1990).
49. Betteridge DJ, Morrell JM. Diabetic patient. In:Clinicians' Guide to Lipids and Coronary Heart Disease. Betteridge DJ, Morrell JM (Eds). Chapman & Hall, London, UK, 232-233 (1998).
50. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24, 683-689 (2001). (Pubitemid 32893993)
51. Adlerberth AM, Rosengren A, Wilhelmsen L. Diabetes and long-term risk of mortality from coronary and other causes in middle-aged Swedish men. A general population study. Diabetes Care 21, 539-545 (1998). (Pubitemid 28172931)
52. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 28, 101-107 (2005). (Pubitemid 40095790)
53. Gonzalez-Baro MR, Lewin TM, Coleman RA. Regulation of triglyceride metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1195-G1199 (2007). (Pubitemid 47084642)
54. Ginsberg HN, Zhang YL, Hernandez-Ono A. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36, 232-240 (2005). (Pubitemid 40755136)
55. Lewis GF, Steiner G. Acute effects of insulin in the control of VLDL production in humans. Implications for the insulinresistant state. Diabetes Care 19, 390-393 (1996). (Pubitemid 26115468)
56. Cornier MA, Dabelea D, Hernandez TL. The metabolic syndrome. Endocr. Rev. 29, 777-822 (2008).
57. McGarry JD. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of Type 2 diabetes. Diabetes 51, 7-18 (2002).
58. Pan DA, Lillioja S, Kriketos AD et al. Skeletal muscle triglyceride levels are inversely related to insulin action Diabetes 46, 983-988 (1997). (Pubitemid 27220998)
59. Poitout V, Robertson RP. Minireview: Secondary b-cell failure in Type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 143(2) 339-342 (2002). (Pubitemid 34107184)
60. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 364(9435), 685-696 (2004). (Pubitemid 39140624)
61. Knopp RH, d'Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with Type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease End points in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 29(7), 1478-1485 (2006). (Pubitemid 44127567)
62. American Diabetes Association. Nutrition principles and recommendations in diabetes (Position Statement). Diabetes Care 27(Suppl. 1), S36-S46 (2004).
63. American Diabetes Association. Physical activity/exercise and diabetes (position statement). Diabetes Care 27, S58-S62 (2004).
64. Reiner Ž. Combined therapy in the treatment of dyslipidemia. Fundam. Clin. Pharmacol. 24, 19-28 (2010).
65. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 27(Suppl. 1), S68-S71 (2004).